Publications

1. Undela K*, Thomas C. (2024). Disproportionality Methods for Signal Detection in Pharmacovigilance. In: Kumar A (ed) Signal Analysis in Pharmacovigilance: Principles and Processes (1st ed.). CRC Press. https://doi.org/10.1201/9781032629940

2. Undela K, Adatia A, Rowe BH, Ferrara G. (2024). Macrolides and Asthma Therapy. In: Rubin BK, Shinkai M. (eds) Macrolides as Immunomodulatory Agents. Progress in Inflammation Research, vol 92. Springer, Cham. https://doi.org/10.1007/978-3-031-42859-3_7  

1. Rathod M, Chunduri P, Thomas C, Pal S, Arab R, Maturu N, Pal S, Barman B, Undela K*. Identifying clinical features and biomarkers associated with interstitial lung disease in rheumatoid arthritis patients. Egyptian Rheumatology and Rehabilitation 2026;53(1):46 - IF 0.7

2. Kasana R, Barthakur M, Velayudhan KV, Barua AR, Borah NC, Undela K*. Eating Epilepsy: Clinico‑Electro‑Imaging Profiles and Treatment Outcomes in Patients from Northeast India. Annals of Indian Academy of Neurology 2026;29(3):426-431 - IF 1.8

3. Thomas C, Saharia N, Varghese V, Das G, Hazarika M, Radhakrishnanand P, Undela K*. Environmental Metal Exposure Patterns and Health-Related Quality of Life in Northeast Indian Gallbladder Cancer Patients: A Metallomic Clustering Study. Exposure and Health 2026;18(3):36 - IF 4.6

4. Battula P, Sree PB, Latha YS, Poojitha KN, Reddy KVS, Krishna SSV, Sri Charan PR, Undela K. Use of proton pump inhibitors and increased risk of fracture in type 2 DM and menopausal women: a systematic review and meta-analysis. African Health Sciences 2026;26(1):134-150 - IF 0.9

5. Donthineni K, Thomas C, Anjali Raveendran KV, Sudha Rani K, Kanukula R, Undela K*. The Quality Assessment of Reporting Methods and Results of Cost-Effectiveness Analyses Conducted on the Indian Population: A Methodological Systematic Review. Value in Health Regional Issues 2026 April 7. https://doi.org/10.1016/j.vhri.2026.101630 - IF 1.5

6. Syed J, Pereira P, Tejeswini CJ, Avarebeel S, Ramesh K, Undela K, Ramesh M, Chalasani SH. Geriatric syndromes, comorbidities, and polypharmacy: Determinants of health-related quality of life in hospitalized older adults in South India. Geriatric Nursing 2026;69:103950 - IF 2.4

7. Rathod M, Kadari M, Kadavath AD, Thomas C, Raveendran A, Jagtap M, Undela K*. Safety of immune checkpoint inhibitors: A systematic review of disproportionality analysis studies. European Journal of Clinical Pharmacology 2026;82(2):35 - IF 2.7 

8. Thomas C, Das A, Varghese V, Battu A, Mohan HR, Das G, Hazarika M, Veettil SK, Rashid M, Undela K*. Gallbladder Cancer Risk Factors in Northeast India: A Mixed-method Integration of Population Attributable Fractions With Global Evidence. Journal of Clinical and Experimental Hepatology 2026;16(2):103470 - IF 3.2  

9. Taj S, Zuber M, Rashid M, Chhabra M, Undela K, Rawal S, Villa Zapata L. Injection-site and dermatologic reactions associated with glucagon-like peptide-1 receptor agonists: Insights from meta-analysis of randomised controlled trials and real-world evidence. Diabetes, Obesity and Metabolism 2026;28(3):1956-1971 - IF 5.7

10. Pavithra N, Ankul Singh S, Begum RF, Undela K, Nirenjen S, Keerthana B, Singh A, Mageswari R, Sabarathinam S. The emerging role of epsilon cells in glucose homeostasis and lipostasis. Obesity Medicine 2026;59:100672

11. Syed J, Thomas C, Kaur B, Pereira P, Jayaram TC, Undela K, et al. Impact of Artificial Intelligence Assisted Drug Therapy Optimization on Drug Related Problems Amongst Older Adult Patients: A Systematic Review. International Journal of Pharmaceutical Investigation 2026;16(1):30-42

12. Syed J, Pereira P, Tejaswini CJ, Avarebeel S, Ramesh K, Ramesh M, Undela K, Chalasani SH. Anticholinergic and sedative medication burden in older adults: an observational analysis. Geriatric Care 2025;11(2):14173 

13. Ali SK, Thomas C, Rathod M, Undela K*. Efficacy and safety of capecitabine therapy in patients with Biliary tract cancer: A systematic review and meta-analysis. Journal of Oncology Pharmacy Practice 2025 Sep 12. https://doi.org/10.1177/10781552251372874 - IF 0.9 

14. Mahesh R, Anjana Das K, Thomas C, Kotakonda SR, Maheshwari K, Undela K*. Identifying potential drug triggers for bullous pemphigoid: a disproportionality analysis of the FDA adverse event reporting system and systematic review of case reports. Cutaneous and Ocular Toxicology 2025;44(4):431-463 - IF 1.3 

15. Zuber M, Thomas C, Taj S, Rashid M, Undela K, Ramanarayanan J, Hernandez-Ilizaliturri FJ, Villa Zapata L. Risk of musculoskeletal disorders associated with Bruton's tyrosine kinase inhibitors: a disproportionality analysis of FAERS database and meta-analysis. Expert Opinion on Drug Safety 2025 Jun 15. https://doi.org/10.1080/14740338.2025.2521358 - IF 3.0 

16. Syed j, Pereira p, Tejeswini CJ, Avarebeel S, Ramesh K, Ramesh M, Undela K, and Chalasani SH. Multi-Criteria Assessment of Potentially Inappropriate Medications in Hospitalized Indian Older Adults: Comparing Beers, STOPP, and FORTA. Journal of Applied Gerontology 2025;45(4):619-630 - IF 2.2 

17. Galigutta RR, Thomas C, Rathod M, Hasik PN, Ray RS, Prakash J, Undela K*. Signal detection of ferric carboxymaltose‑induced serious adverse events: disproportionality analysis of FAERS and VigiBase data and systematic review of case reports. European Journal of Clinical Pharmacology 2025;81(7):1081-1096 – IF 2.4 

18. Alsalloum MA, Alsalloum AS, Thabit AK, Undela K. Impact of Augmented Renal Clearance on Infection Treatment Outcomes among Critically Ill Patients: A Systematic Review and Meta-Analysis. Saudi Journal of Clinical Pharmacy 2025;4(2):35-48 

19. Thiyagarajan G, Nagasubramanian VR, Ravichandran SL, Baskaran P, Thangam DC, Sankaranarayanan RK, Undela K, Sridevi B, Pelluri R, Gurram PC, Rajangam J. Acceptance and reluctance of COVID-19 vaccination among the general population: a systematic review and meta-analysis of cross-sectional studies. Journal of Applied Pharmaceutical Science 2025;15(5):14-23  

20. Hasik PN, Thomas C, Hazarika M, Undela K*. Ocular adverse events associated with platins: a disproportionality analysis of pharmacovigilance data and extensive systematic review of case reports. Expert Opinion on Drug Safety 2025;24(10):1143-1156 – IF 3.0 

21. Keerthanaa B, Appaji R, Thomas L, Baral T, Skanda N, Chaithra, Sonal Sekhar M, Saravu K, Undela K, Rao M. Characteristics of isoniazid-induced psychosis: a systematic review of case reports and case series. European Journal of Clinical Pharmacology 2024;80(11):1725-1740 – IF 2.4 

22. Galigutta RR, Hasik PN, Thomas C, Undela K*. Efficacy and safety of luseogliflozin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Endocrine 2024;86(2):620-630 – IF 3.7 

23. Niveditha M, Kasana R, Barua AR, Barthakur M, Undela K*. Assessment of disease pattern and drug utilization among neurology intensive care unit patients in a developing country: an observational analysis. Hospital Practice (1995) 2024;52(3):77-83

24. Muhammed A, Thomas C, Kalaiselvan V, Undela K*. Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials. Expert Opinion on Drug Safety 2024;23(6):731-742 – IF 3.1 

25. Undela K*, Kalaiselvan V, Gudi SK, Viswam SK, Ali SK. Risk of serious skin and subcutaneous tissue disorders for nimesulide among the pediatric population: a jeopardy identified through the analysis of global individual case safety reports. Expert Opinion on Drug Safety 2024;23(8):1021-1026 – IF 3.1 

26. Niveditha M, Kasana R, Undela K*. Characteristics and Outcomes of Japanese Encephalitis in the Northeast State of India: A Retrospective Case Series Study. Hospital Practices and Research 2023;8(2):234-240

27. Kasana R, Thomas C, Das G, Hazarika M, Undela K*. Statin use and risk of cancer: An umbrella meta-analysis. Annals of Oncology Research and Therapy 2023;3(1):14-31

28. Kinattingal N, Mehdi S, Undela K, Wani SUD, Almuqbil M, Alshehri S, Shakeel F, Imam MT, Manjula SN. Prevalence of Cognitive Decline in Type 2 Diabetes Mellitus Patients: A Real-World Cross-Sectional Study in Mysuru, India. Journal of Personalized Medicine 2023;13(3):524 – IF 3.4 

29. Jagi JL, Thomas C, Gudi SK, Undela K*. Efficacy, safety, and tolerability of isoniazid preventive therapy for tuberculosis in people living with HIV: a systematic review and meta-analysis. AIDS 2023;37(3):455-465 – IF 3.8 

30. Sureshkumar K, Durairaj M, Srinivasan K, Goh KW, Undela K, Mahalingam VT, Ardianto C, Ming LC, Ganesan RM. Effect of L-Carnosine in Patients with Age-Related Diseases: A Systematic Review and Meta-Analysis. Frontiers in Bioscience Landmark 2023; DOI: 10.31083/j.fbl2801018 – IF 3.1

31. Gadidala SK, Johny E, Thomas C, Nadella M, Undela K, Adela R. Effect of garlic extract on markers of lipid metabolism and inflammation in coronary artery disease (CAD) patients: A systematic review and meta-analysis. Phytotherapy Research 2023;37(6):2242-2254 – IF 7.2 

32. Undela K, Gurumurthy P, Sujatha MS. Impact of medical conditions and medications received during pregnancy on adverse birth outcomes: A hospital-based prospective case–control study. Perspectives in Clinical Research 2023;14(1):10-15 

33. Puvvada RK, Adusumilli P, Maddukuri RK, Samaksha PB, Annam MG, Undela K*. Efficacy and Safety of Hydroxychloroquine in the Treatment of Type-2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Journal of Young Pharmacists 2022;14(4):402-407

34. Palapra H, Viswam SK, Kalaiselvan V, Undela K*. SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports. International Journal of Clinical Pharmacy 2022; DOI: 10.1007/s11096-022-01476-7 – IF 2.305

35. Konikuzhiyil MH, Balasubramaniam V, Undela K, Ponnusankar S. Prediabetes education: the underutilized tool of diabetes prevention among Indian population. Indian Journal of Pharmaceutical Education and Research 2022;56(4, Suppl):S613-S619 – IF 0.843

36. George R, Thomas C, Joy CA, Varghese B, Undela K, Adela R. Comparative efficacy and safety of oral nifedipine with other antihypertensive medications in the management of hypertensive disorders of pregnancy: a systematic review and meta-analysis of randomized controlled trials. Journal of Hypertension 2022;40(10):1876-1886 – IF 4.776

37. Sah SK, Shariff A, Pathakamuri N, Ramaswamy S, Ramesh M, Undela K, Srikanth MS, Pramod Kumar TM. Antifungal therapy in the management of fungal secondary infections in COVID-19 patients: A systematic review and meta-analysis. PLoS ONE 2022;17(7):e0271795 – IF 3.752

38. Undela K, Goldsmith L, Kew KM, Ferrara G. Macrolides versus placebo for chronic asthma. Cochrane Database of Systematic Reviews 2021; Issue 11: Art. No.: CD002997 – IF 9.266

39. Khatiwada AP, Undela K, Kumar SS and Shrestha S. Potential and actual drug-drug interactions among patients with cardiovascular disease: a comprehensive analysis of data from a tertiary care hospital in South India. International Journal of Pharmaceutical Sciences and Research 2021;12(9):5093-5101

40. Parthasarathi A, Kumar R, Undela K, Siddaiah JB, Mahesh PA. The extent of formal tobacco cessation training received by student health professionals and the prevalence of tobacco use among them: a cross-sectional study. Welcome Open Research 2021;6:226

41. Puvvada RK, Undela K, Samaksha PB, Kuruvilla AV, Gupta BS. Knowledge and Perception of Pharmacy Practice Students on Causality Assessment of Adverse Drug Reactions. Advances in Pharmacology and Pharmacy 2021;9(4):94-99

42. Parthasarathi A, Shankar M, Mahesh PA, Madhivanan P, Lokesh KS, Undela K, Krishna MT. Determinants of tobacco use and nicotine dependence among healthcare students and their undergraduate peers. Current Respiratory Medicine Reviews 2021;17(3):139-150

43. Puvvada RK, Undela K, Parthasarathi G. Prevalence, Risk Factors, and Cost Burden of Fall-Related Hospital Admissions in India. The Senior Care Pharmacist 2021;36(7):343-349

44. Ann Abraham D, Undela K, Udayakumar N, Rajanandh MG. Effect of L-Carnosine in children with autism spectrum disorders: a systematic review and meta-analysis of randomised controlled trials. Amino Acids 2021;53(4):575-585 – IF 3.520

45. Samaksha PB, Undela K, Puvvada RK, Gupta BS, Kishore M, Palaksha S. Psychological Impact of COVID-19 Lockdown among Healthy Individuals in India: A Self-Assessed Cross-Sectional Study. International Journal of Pharmaceutical Research 2021;13(2):1659-1671

46. Undela K*, Joy N, Gurumurthy P, Sujatha MS. Knowledge, beliefs, and practice of pregnant women regarding medication use during pregnancy: a hospital-based cross-sectional study. Journal of Obstetrics and Gynaecology 2021;41(4):522-526 – IF 0.807

47. Puvvada RK, Undela K, Palaksha S, Gupta BS. Knowledge and Beliefs of General Public of India on COVID-19: A Cross-sectional Survey. EAS Journal of Pharmacy and Pharmacology 2020;2(5):21-27

48. Gudi SK, Chhabra M, Undela K, Venkataraman R, Mateti UV, Tiwari KK, Nyamagoud S. Knowledge and beliefs towards universal safety precautions during the coronavirus disease (COVID‑19) pandemic among the Indian public: a web‑based cross‑sectional survey. Drugs & Therapy Perspectives 2020; DOI: 10.1007/s40267-020-00752-8

49. Undela K, Gudi SK. Assumptions for disparities in case-fatality rates of coronavirus disease (COVID-19) across the globe. European Review for Medical and Pharmacological Sciences 2020;24(9):5180-5182 – IF 3.024

50. Rashid M, Ramesh M, Shamshavali K, Dang A, Patel H, Undela K. Efficacy and Safety of Non-steroidal Anti-androgens in Patients with Metastatic Prostate Cancer: Meta-analysis of Randomized Controlled Trials. Reviews on Recent Clinical Trials 2020;15(1):34-47

51. Rashid M, Chhabra M, Kashyap A, Undela K, Gudi SK. Prevalence and Predictors of Self-Medication Practices in India: A Systematic Literature Review and Meta-Analysis. Current Clinical Pharmacology 2019;15(2):90-101

52. Pramod BR, Mehdi S, Undela K, Kishor M, Vengal Rao P, Krishna KL. Lifestyle and substance use-an important cause for treatment-resistant depression and major depressive disorders. Drug Invention Today 2019;11(S2):284-290

53. Undela K, Mohammed BTS, Gurumurthy P, Doreswamy SM. Impact of preterm birth and low birth weight on medical conditions, medication use and mortality among neonates: a prospective observational cohort study. World Journal of Pediatrics 2019;15(3):281-288 – IF 1.169

54. Rashid M, Kashyap A, Undela K. Valproic acid and Stevens-Johnson syndrome: a systematic review of descriptive studies. International Journal of Dermatology 2019;58(9):1014-1022 – IF 1.794

55. Menon VB, Ramesh M, Pereira P, Raviprakash VC, Undela K. Inappropriate prescribing of antimalarial therapy for the treatment of undifferentiated febrile illness among the elderly. Journal of Pharmacy Practice and Research 2018;48(6):530-536

56. Parthasarathi G, Harugeri A, Undela K. Pharmacovigilance Research in India: Five-Year Literature Review. Proceedings of Indian National Science Academy 2018;84(1):225-232

57. Adusumilli PK, Rajendra Prasad S, Parthasarathi G, Undela K. Assessment of adverse drug reactions to antiretroviral agents among HIV patients. Journal of Applied Pharmaceutical Science 2018;8(2):79-82

58. Varghese A, Undela K, Parthasarathi G, Narahari MG. Impact of diabetes on the risk of geriatric conditions among patients seen in a tertiary care hospital in India. International Journal of Health Allied Sciences 2017;6(3):169-76

59. Undela K*, Shah CS, Mothe RK. Statin use and risk of cancer: An overview of meta-analyses. World Journal of Meta-Analysis 2017;5(2):41-53

60. Mishra A, Adusumilli PK, Undela K, Dileep K. Severe upper gastrointestinal bleeding with gastric ulcer and anaemia secondary to prolonged use of aspirin and clopidogrel – A case report. International Journal of Allied Medical Sciences and Clinical Research 2016;4(4):727-730

61. Christudas MJ, Gupta BS, Undela K, Isaac NM, Ram D, Ramesh M. Assessment of impact of pharmacophilia and pharmacophobia on medication adherence in patients with psychiatric disorders: A cross-sectional study. Indian Journal of Pharmacology 2016;48(6):701-705 – IF 0.599

62. Adusumilli PK, Shivaswamy RP, Parthasarathi G, Undela K. Association of highly active antiretroviral therapy to diabetes mellitus and dyslipidemia in HIV/AIDS patients: A review article. International Journal of Universal Pharmacy and Bio Sciences 2016;5(4):68-80

63. Adusumilli PK, Shivaswamy RP, Parthasarathi G, Undela K. Management of immune reconstitution inflammatory syndrome in HIV patients. International Journal of Universal Pharmacy and Bio Sciences 2016;5(3):303-311

64. Varghese NA, Gangadhar ST, Menon VB, Undela K, Ramesh M. Enoxaparin induced maculopapular rash. Indian Journal of Pharmacy Practice 2016;8(4):199-201

65. Kew KM, Undela K, Kotortsi I, Ferrara G. Macrolides for chronic asthma. Cochrane Database of Systematic Reviews 2015;9:CD002997 – IF 6.032

66. Isaac NM, Menon VB, Christudas MJ, Undela K, Ram D. Comparative review of a novel melatonergic antidepressant drug – Agomelatine. World Journal of Pharmaceutical Research 2015;4(7):1323-1334

67. Undela K, Parthasarathi G, John SS. Impact of antidepressants use on risk of myocardial infarction: A systematic review and meta-analysis. Indian Journal of Pharmacology 2015;47(3):256-262 – IF 0.691

68. Menon VB, Kurian J, Undela K, Ramesh M, Gowdappa HB. Phenytoin Toxicity: A Case Report. Journal of Young Pharmacists 2015;7(3):272-275

69. Bansal D, Mangla S, Undela K, Gudala K, D'Cruz S, Sachdev A, Tiwari P. Measurement of adult antimicrobial drug use in tertiary care teaching hospital using defined daily dose and dose of therapy. Indian Journal of Pharmaceutical Sciences 2014;76(3):211-217 – IF 0.296

70. Undela K*, Gopal M. Saroglitazar: the world’s first drug for treating diabetic dyslipidemia. Journal of Comprehensive Pharmacy 2014;1(1):11-14

71. Bansal D, Gudala K, Undela K. Statins for preventing colorectal adenoma and carcinoma. Cochrane Database of Systematic Reviews 30 May 2014;5:CD011137 – IF 5.939

72. Undela K, Bansal D, D’Cruz S, Sachdev A, Tiwari P. Prevalence and Determinants of Use of Potentially Inappropriate Medications in Elderly Inpatients: A Prospective Study in Tertiary Health Care Setting. Geriatrics & Gerontology International 2014;14(2):251-258 – IF 2.167

73. Undela K*. Sirturo (Bedaquiline): The first new anti-tubercular drug in decades. World Journal of Meta-analysis 2013;1(1):8-9

74. Undela K*, Gudala K, Malla S, Bansal D. Statin use and risk of Parkinson’s disease: a meta-analysis of observational studies. Journal of Neurology 2013;260(1):158-165 – IF 3.473

75. Bansal D, Bhansali A, Gudala K, Undela K, Tiwari P. Type 2 diabetes and risk of prostate cancer: A meta-analysis of observational studies. Prostate Cancer and Prostatic Diseases 2013;16(2):151-158 – IF 2.421

76. Bansal D, Undela K, D’Cruz S, Schifano F. Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS ONE 2012;7(10):e46691 – IF 4.092

77. Undela K*, Vallakatla S, Bansal D. Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Research and Treatment 2012;135(1):261-269 – IF 4.346

78. Undela K*. Biogenerics or Biosimilars: An overview of the current situation in India. International Journal of Medical and Pharmaceutical Sciences 2011;1(7):1-10

79. Rasheed A, Undela K, Sivakrishna Reddy P, Mishra A. Synthesis and characterization of novel dextran-conjugated macromolecules of Aceclofenac. Ars Pharmaceutica 2011;52(1):5-11 

*Corresponding author

1. 1. Thomas C, Undela K, Varghese V. Economic Burden and Cost Effectiveness of Advanced Gallbladder Cancer Treatment in Northeast India: A Dual Phase Assessment. Value in Health 2026;29(6,S1):S182 – IF 6.2

   2. Thomas C, Das G, Hazarika M, Saharia N, Undela K. Urinary Arsenic and Other Heavy Metals in Gallbladder Cancer Patients: A Pilot Study Correlating Exposure with Drinking Water and Assessing Carcinogenic Risk in Northeast India. Clinical Cancer Research 2025;31(23_Supplement):C018 – IF 10.2

   3. Kasana R, Haripriya NB, Barua AR, Barthakur M, Undela K. Evaluating the Disease Spectrum and Cost of Care Among Neurology Inpatients in Northeast India: Insights from a Real World, Hospital Based Study. Value In Health Regional Issues 2025;49(S1):101215 – IF 1.5

   4. Kasana R, Biju SM, Barua AR, Barthakur M, Undela K. Assessment of Stroke Patterns and Risk Factors in Northeast India: A Hospital-Based Prospective Study. Value In Health Regional Issues 2025;49(S1):101193 – IF 1.5

   5. Barthakur M, Kasana R, Barua AR, Undela K. Eating Epilepsy: Clinico-Electro-Imaging Profiles and Treatment Outcomes in Patients from Northeast India. International Journal of Epilepsy 2025;11(S02):1-56

   6. Undela K, Rathod M, Thomas C, Galigutta RR, Hasik PN. Identifying the Safety Signals for Adverse Events Causing Mortality Due to Ferric Carboxymaltose: A Disproportionality Analysis of Spontaneous Reports and Extensive Systematic Review. Pharmacoepidemiology and Drug Safety 2024;33(S2):305 – IF 2.4

   7. Varghese V, Thomas C, Undela K, Nair G. Computational Drug Repurposing for Gallbladder Cancer Integrated with Pharmacovigilance Approach. Pharmacoepidemiology and Drug Safety 2024;33(S2):169 – IF 2.4

   8. Hasik PN, Thomas C, Undela K. Ocular Adverse Events Associated with Platins: A Disproportionality Analysis of Pharmacovigilance Data and Extensive Systematic Review of Case Reports. Pharmacoepidemiology and Drug Safety 2024;33(S2):176 – IF 2.4

   9. Kasana R, Barua AR, Barthakur M, Undela K. Evaluation Epilepsy Patterns and Treatment Approaches: Findings from a Neurological Tertiary Care Hospital. Pharmacoepidemiology and Drug Safety 2024;33(S2):288 – IF 2.4

   10. Raj K, Thomas C, Undela K, Kakati K. Machine Learning and Deep Learning Techniques for the Survival Prediction of Oropharyngeal Squamous Cell Carcinoma: Ahead of the Pack. Pharmacoepidemiology and Drug Safety 2024;33(S2):347 – IF 2.4

   11. Galigutta RR, Hasik PN, Thomas C, Undela K. Efficacy and Safety of Luseogliflozin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Pharmacoepidemiology and Drug Safety 2024;33(S2):359 – IF 2.4

   12. Thomas C, Hasik PN, Galigutta RR, Undela K. Risk of Neonatal and Maternal Adverse Events of Oral Anti-hypertensive Medications Used in Pregnancy: Evidence Synthesis from a Disproportionality Analysis. Pharmacoepidemiology and Drug Safety 2024;33(S2):482 – IF 2.4

   13. Battu A, Undela K, Thomas C. Implementation of Clinical Pharmacist's Services in Patients Receiving Oral Oncolytics and its Effects on Medication Adherence and Quality of Life: A Hospital-Based Prospective Interventional Study. Pharmacoepidemiology and Drug Safety 2024;33(S2):513 – IF 2.4

   14. Zuber M, Thomas C, Borate S, Undela K, Zapata LV. Bruton's Tyrosine Kinase-Induced Musculoskeletal Disorders: A Real-World Safety Data Analysis of FAERS Database and Meta-Analysis of Randomized Controlled Trials. Pharmacoepidemiology and Drug Safety 2024;33(S2):528 – IF 2.4

   15. Syed J, Chalasani SH, Thomas C, Undela K, Madhan R, Patil V. Effects of AI-Assisted Drug Therapy Management on Medication-Related Issues in Elderly Patients: A Systematic Review. Pharmacoepidemiology and Drug Safety 2024;33(S2):571 – IF 2.4

   16. Thomas C, Varghese V, Raj K, Undela K. Cost-Effectiveness of Triple Therapy Compared to Dual Therapy in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. Pharmacoepidemiology and Drug Safety 2024;33(S2):684 – IF 2.4

   17. Battu A, Thomas C, Shilpa A, Undela K. The impact of nicotine replacement therapy on maternal-neonatal outcomes and smoking cessation in pregnant women: A systematic review and meta-analysis. Pharmacoepidemiology and Drug Safety 2023;32(S1):542 – IF 2.6

   18. Ali SK, Thomas C, Hazarika M, Khanikar D, Undela K. Capecitabine-induced adverse reactions in patients with biliary tract cancer: Evidence from spontaneous reporting data analysis and systematic review & meta-analysis. Pharmacoepidemiology and Drug Safety 2023;32(S1):498 – IF 2.6

   19. Thomas C, Undela K. Risk of cholelithiasis and cholecystitis for antidiabetic medications: Evidence synthesis from a disproportionality analysis. Pharmacoepidemiology and Drug Safety 2023;32(S1):485 – IF 2.6

   20. Thomas C, Kanukula R, Ali SK, Mahesh R, Das G, Hazarika  M, Undela K. Human health risk assessment and meta-analysis of arsenic-contaminated drinking water in endemic regions of India. Pharmacoepidemiology and Drug Safety 2023;32(S1):459 – IF 2.6

   21. Shilpa A, Thomas C, Kakati K, Krishnatreya M, Baishya N, Undela K. Evaluation of years of potential productive life lost (YPPLL) due to premature mortality from head and neck cancer in northeast India. Pharmacoepidemiology and Drug Safety 2023;32(S1):393 – IF 2.6

   22. Vijayasangeetha G, Thomas C, Das G, Hazarika M, Undela K. Economic burden of gallbladder cancer in northeast India: A hospital-based prospective observational cost-analysis study. Pharmacoepidemiology and Drug Safety 2023;32(S1):385 – IF 2.6

   23. Mahesh R, Thomas C, Ali SK, Undela K. The influence of timing of cholecystectomy on the incidence of post-ERCP pancreatitis: A systematic review & meta-analysis. Pharmacoepidemiology and Drug Safety2023;32(S1):260 – IF 2.6

   24. Preethi C, Pal S, Arab RJ, Maturu NV, Thomas C, Undela K. Assessment of potential risk factors and biochemical predictors for the interstitial lung disease in patients with rheumatoid arthritis. Pharmacoepidemiology and Drug Safety 2023;32(S1):248 – IF 2.6

   25. Mamidi N, Kasana R, Barua AR, Borthakur M, Undela K. Assessment of the disease pattern and drug utilization among the neuro ICU patients. Pharmacoepidemiology and Drug Safety 2023;32(S1):241 – IF 2.6

   26. Undela K, Gudi SK, Grundmark B, Kalaiselvan V. Risk of Serious Skin and Subcutaneous Tissue Disorders for Nimesulide among the Pediatric Population: A Jeopardy Identified through the Analysis of Global Individual Case Safety Reports. Pharmacoepidemiology and Drug Safety 2022;31(S2):652 – IF 2.732

   27. Nethravathi G, Mudimala P, Thomas C, Undela K. Quality Assessment of Latest National Comprehensive Cancer Network Guidelines Using The AGREE-II Instrument and RIGHT Statement. Pharmacoepidemiology and Drug Safety 2022;31(S2):498 – IF 2.732

   28. Thomas C, Satish M, Undela K. Efficacy and Safety of Amphotericin B and Oral Miltefosine Combination in Patients with Visceral Leishmaniasis: A Systematic Review and Meta-Analysis. Pharmacoepidemiology and Drug Safety 2022;31(S2):345-346 – IF 2.732

   29. Thomas C, Chalasani S, Murti K, Undela K, Ramesh M. Efficacy and Safety of Inhaled Corticosteroid Containing Combinations in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review and Meta-Analysis. Pharmacoepidemiology and Drug Safety 2022;31(S2):346-347 – IF 2.732

   30. Donthineni K, Thomas C, Undela K. The Quality of Reporting Methods and Results of Cost-Effectiveness Analyses in India: A Methodological Systematic Review. Pharmacoepidemiology and Drug Safety2022;31(S2):396 – IF 2.732

   31. Maske AA, Thomas C, Undela K. Risk of Adverse Events Associated with Novel Oral Anticoagulant (Apixaban): A Systematic Review and Meta-Analysis. Pharmacoepidemiology and Drug Safety 2022;31(S2):279-280 – IF 2.732

   32. Lawrance G, Thomas C, Undela K. Cardiovascular Efficacy and Safety of Incretin Mimetics and Sodium-Glucose Co-Transporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of RCTs. Pharmacoepidemiology and Drug Safety 2022;31(S2):280-281 – IF 2.732

   33. Muhammed A, Thomas C, Undela K. Risk of Pancreatitis and Pancreatic Carcinoma for Antidiabetic Medications: Evidence Synthesis from Disproportionality Analysis. Pharmacoepidemiology and Drug Safety2022;31(S2):37 – IF 2.732

   34. D'Souza J, Furlan G, Undela K. Drug Safety in Geriatric Patients and the Need for a New ISoP Special Interest Group. Drug Safety 2022;45(10):1289 – IF 5.228

   35. Laxmi JJ, Thomas C, Undela K. Efficacy and safety of isoniazid preventive therapy (IPT) in people living with HIV: A systematic review and meta-analysis. Pharmacoepidemiology and Drug Safety 2021;30(S1):212 – IF 2.890

   36. Joshy AS, Surendran S, Undela K. Can we really trust the findings of the COVID-19 research? Quality assessment of the randomized controlled trials published on COVID-19. Pharmacoepidemiology and Drug Safety2021;30(S1):158 – IF 2.890

   37. Hibathulla P, Undela K. Identification of novel safety signals of SGLT2 inhibitors: Analysis of US FDA and global safety databases. Pharmacoepidemiology and Drug Safety 2021;30(S1):242 – IF 2.890

   38. Samaksha PB, Undela K, Puvvada RK, Gupta B, Rao KM, Palaksha S. To Assess the Psychological Impact of COVID-19 Lockdown Among Healthy Individuals in India. Value in Health 2020;23(S2):S589 – IF 4.748

   39. Kumar AP, Bhoopathi D, Undela K, Veerakumar V. Comparison of mental health status among the south Indian healthcare professional students during COVID-19 pandemic’s quarantine period: A cross-sectional study. Journal of Global Trends in Pharmaceutical Sciences 2020;11:NACP47

   40. Kumar AP, Undela K, Bhoopathi D. Knowledge, attitude and practice relating to antibiotic use among pharmacy students in south India. Journal of Global Trends in Pharmaceutical Sciences 2020;11:NACP46

   41. Mandalapu L, Janardan RM, Patel J, Vinod VS, Undela K. Evaluation of Prescribing Trends and Assessment of Drug Related Problems in Patients with Acute Coronary Syndrome. Value in Health 2019;22(S3):S566 – IF 5.037

   42. Undela K. Terminologies used in Pharmacovigilance; Pharmacovigilance Methods. Pharma Web Newsletter of Tamilnadu Pharmaceutical Sciences Welfare Trust 2017;35:44-57

   43. Undela K, Joshi D, Ramesh M. Incidence of Adverse Drug Reactions among Elderly Patients: A Systematic Review and Meta-analysis. Pharmacoepidemiology and Drug Safety 2017;26(S2):164 – IF 2.552

   44. Menon VB, Ramesh M, Undela K, Pereira P, CR V. Identification and Evaluation of Clinical and Economic Impact of Potential Drug Related Problems in the Elderly. Value in Health 2017;20(5):A282 – IF 4.235

   45. Undela K. Assessment of Prices of Essential Medicines for Chronic Diseases Prevalent in the Asia Pacific Region. Value in Health 2016;19(7):A460 – IF 3.824

   46. Undela K. Assessment of Price of Essential Medicines in India. Value in Health 2016;19(7):A460-A461 – IF 3.824

   47. Menon VB, Ramesh M, Pereira P, Undela K, Hathur BG. Cost Implications of Inappropriate Prescribing of Anti-Malarial Therapy for Treatment of Undifferentiated Febrile Illness Among Elderly. Value in Health2016;19(7):A402 – IF 3.824

   48. Undela K, Pramod A, Parthasarathi G. Identification of Potential Signals of Serious Risks for Sitagliptin: Analysis of Spontaneous Adverse Event Reports in VigiBase®. Pharmacoepidemiology and Drug Safety 2016;25(S3):431-432 – IF 2.908

   49. Nguyen TA, Qiang S, Wang H, Undela K, Vitry A. Availability and prices of essential medicines for chronic diseases in the Asia Pacific region: a secondary analysis. International Journal of Pharmacy Practice2016;24(S2):48-49

   50. Nguyen TA, Qiang S, Wang H, Undela K, Vitry A. Availability and prices of essential medicines for chronic diseases in older people in the Asia Pacific Region. Journal of Pharmaceutical Policy and Practice 2015;8(S1):P3 

   51. Parthasarathi G, Jojo J, Ramesh M, Undela K, Ram D. Prevalence and predictors of medication non-adherence in patients with mental disorders: a cross-sectional study. Pharmacoepidemiology and Drug Safety 2015;24(S1):163 – IF 2.939

   52. Undela K, Varghese A, Parthasarathi G, Narahari MG. Assessment of Effect of Geriatric Conditions on Activities of Daily Living with the Elderly. Pharmacoepidemiology and Drug Safety 2014;23(S1):434 - IF 3.172

   53. Parthasarathi G, Varghese A, Undela K, Narahari MG. The Risk of Geriatric Conditions in Patients with Diabetes Mellitus and Hypertension. Pharmacoepidemiology and Drug Safety 2014;23(S1):435 - IF 3.172

   54. Undela K, Bansal D, Gudala K, Esam H. Sources of knowledge of commonly used by Cochrane authors in developing countries. Cochrane Database of Systematic Reviews 2014;Suppl:113 - IF 5.939

   55. Undela K, Parthasarathi G, John SS. Tricyclic Antidepressants Use and Risk of Myocardial Infarction: A Systematic Review and Meta-Analysis of Observational Studies. Value in Health 2014;17(3):A107 – IF 2.891

   56. Raval A, Thakker D, Undela K, Vyas A, Kachhadiya R, Ubhadiya B. Clinical outcomes of dapagliflozin in patients with type 2 diabetes mellitus: A meta-analysis of randomised controlled clinical trials. Value in Health2014;17(3):A240 – IF 2.891

   57. Bansal D, Undela K, Sachdev A, D’Cruz S. Comparative Evaluation of the Appropriateness of the Prescribing in Geriatrics Inpatients Using Beers Criteria 2012 and 2003. Value in Health 2013;16(7):A673 – IF 2.191

   58. Parthasarathi G, Undela K, John SS. Use of Antidepressants and Risk of Developing First-Time Acute Myocardial Infarction: A Systematic Review and Meta-Analysis of Observational Studies. Pharmacoepidemiology and Drug Safety 2013;22(S1):78-79 – IF 2.897

   59. Undela K, Chaitanya GK, Parthasarathi G. Impact of patient medication counselling on medication adherence in a cardiology outpatient clinic. Hong Kong Pharmaceutical Journal 2013;20(3):137

   60. Parthasarathi G, Reddy BA, Undela K. Assessment of adverse drug reactions to anesthetic agents in a tertiary care hospital. Hong Kong Pharmaceutical Journal 2013;20(3):155

   61. Undela K, Gudala K, Malla S, Bansal D. The role of statin use on incidence of Parkinson's disease: A meta-analysis of observational studies. Movement Disorders 2013;28(Supplement S1):S296 – IF 4.558

   62. Undela K, Vallakatla S. Statin use and risk of breast cancer: a meta-analysis of 24 observational studies. Value in Health 2012;15(7):A413 – IF 2.191

   63. Bansal D, Gudala K, Undela K, Tiwari P, Bhansali A. Decreased risk of prostate cancer in type 2 diabetes patients: a meta-analysis of cohort studies. Value in Health 2012;15(7):A655 – IF 2.191

   64. Undela K, Bansal D, D’Cruz S, Sachdev A, Tiwari P. Scope of improving medication use in elderly inpatients. Journal of Indian Academy of Geriatrics 2012;8:21

   65. Bansal D, Undela K, D’Cruz S, Sachdev A, Tiwari P. Drug burden index and factors associated with polypharmacy in elderly inpatients. Journal of Indian Academy of Geriatrics 2012;8:19

Editorial Board Member for

1. BMC Public Health

2. SPER Journal of Clinical Pharmacy and Pharmacology

3. International Journal of Pharmaceutical Sciences

4. Journal of Comprehensive Pharmacy

5. World Journal of Meta-analysis

6. American Journal of Cancer Epidemiology and Prevention

Peer Reviewer for

7. Annals of Medicine

8. Heliyon – Cell Press

9. The International Journal of Tuberculosis and Lung Disease

10. Current Psychiatry Research and Reviews

11. JAMA Network Open

12. Journal of Pharmaceutical Health Services Research

13. Frontiers in Digital Health

14. PLOS ONE

15. Clinical Epidemiology and Global Health

16. Environmental Research

17. BMC Pulmonary Medicine

18. Asian Journal of Psychiatry

19. Frontiers in Pharmacology

20. Frontiers in Public Health

21. Nursing Open

22. Preventive Medicine Reports

23. The International Journal of Neuropsychopharmacology

24. Drug, Healthcare and Patient Safety

25. Patient Preference and Adherence

26. World Journal of Psychiatry

27. International Journal of Pharma and Bio Sciences

28. Critical Reviews in Toxicology

29. International Journal of Clinical Practice

30. International Journal of Pharmaceutical Research

31. World Journal of Clinical Cases

32. Cancer Medicine

33. Journal of Integrated Health Sciences

34. Acta Endocrinologica

35. IJC Heart & Vasculature

36. International Journal of Diabetes in Developing Countries

37. International Journal of Health and Allied Sciences

38. Journal of Clinical and Diagnostic Research

39. Drugs & Therapy Perspectives

40. Pharmacoepidemiology and Drug Safety

41. Journal of Pharmacy Practice

42. World Journal of Hepatology

43. Annals of Neurology

44. Cancer Investigation

45. Drugs

46. European Journal of Neurology

47. Brest Cancer Research and Treatment

48. Indian Journal of Pharmacy Practice

49. World Journal of Gastroenterology

50. Reviewer for “International Society for Pharmacoepidemiology” Conference Abstracts

51. Reviewer for “International Society for Pharmacoeconomics and Outcomes Research” Conference Abstracts